Of 6075 patients with DLBCL registered in LYFO who received at least one cycle of R‐CHOP/R‐CHOP‐like therapy in the inclusion period, only 382 patients lacked IPI/NCCN‐IPI variables, while one lacked data on vital status. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.